Evidence map›Paper›PMID 29141939›Full record

Trial reportAmerican journal of physiology. Renal physiology2018

Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.

Harindra Rajasekeran, Heather N Reich, Michelle A Hladunewich, Daniel Cattran, Julie A Lovshin, Yuliya Lytvyn, Petter Bjornstad, Vesta Lai, Josephine Tse, Leslie Cham and 8 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of physiology. Renal physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06890143 (The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06890143 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2025 to 2027Enrolled44ConditionsPediatric Hereditary Kidney DiseasesArmsDapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Harindra RajasekeranDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Heather N ReichDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Michelle A HladunewichDepartment of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, Ontario , Canada.
Daniel CattranDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Julie A LovshinDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Yuliya LytvynDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Petter BjornstadDepartment of Pediatric Endocrinology, University of Colorado School of Medicine , Aurora, Colorado.
Vesta LaiDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Josephine TseDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Leslie ChamDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
Syamantak MajumderKeenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute, St. Michael's Hospital , Toronto, Ontario , Canada.
Bridgit B BowskillKeenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute, St. Michael's Hospital , Toronto, Ontario , Canada.
M Golam KabirKeenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute, St. Michael's Hospital , Toronto, Ontario , Canada.
Suzanne L AdvaniKeenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute, St. Michael's Hospital , Toronto, Ontario , Canada.
Ian W GibsonDepartment of Pathology, University of Manitoba , Winnipeg, Manitoba , Canada.
Manish M SoodOttawa Hospital Research Institute, University of Ottawa , Ottawa, Ontario , Canada.
Andrew AdvaniKeenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute, St. Michael's Hospital , Toronto, Ontario , Canada.
David Z I CherneyDepartment of Medicine, Division of Nephrology, University Health Network, University of Toronto , Toronto, Ontario , Canada.
St. Michael's Hospital · CAUniversity Health Network · CAUniversity of Toronto · CAHealth Sciences Centre · CAOttawa Hospital · CAUniversity of Colorado Denver · USUniversity of Manitoba · CA

Funding

Training Program in Diabetes ResearchT32DK063687 · UNIVERSITY OF COLORADO DENVER · 2002 to 2025
$968k
NIDDK NIH HHS T32 DK063687
6 · The paper itself

Abstract

Focal segmental glomerulosclerosis (FSGS) is an important cause of nondiabetic chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibition (SGLT2i) therapy attenuates the progression of diabetic nephropathy, but it remains unclear whether SGLT2i provides renoprotection in nondiabetic CKD such as FSGS. The primary aim of this pilot study was to determine the effect of 8 wk of dapagliflozin on glomerular filtration rate (GFR) in humans and in experimental FSGS. Secondary end points were related to changes in renal hemodynamic function, proteinuria, and blood pressure (BP). GFR (inulin) and renal plasma flow (para-aminohippurate), proteinuria, and BP were measured in patients with FSGS ( n = 10), and similar parameters were measured in subtotally nephrectomized (SNx) rats. In response to dapagliflozin, changes in GFR, renal plasma flow, and 24-h urine protein excretion were not statistically significant in humans or rats. Systolic BP (SBP) decreased in SNx rats (196 ± 26 vs. 165 ± 33 mmHg; P < 0.001), whereas changes were not statistically significant in humans (SBP 112.7 ± 8.5 to 112.8 ± 11.2 mmHg, diastolic BP 71.8 ± 6.5 to 69.6 ± 8.4 mmHg; P = not significant), although hematocrit increased (0.40 ± 0.05 to 0.42 ± 0.05%; P = 0.03). In archival kidney tissue from a separate patient cohort, renal parenchymal SGLT2 mRNA expression was decreased in individuals with FSGS compared with controls. Short-term treatment with the SGLT2i dapagliflozin did not modify renal hemodynamic function or attenuate proteinuria in humans or in experimental FSGS. This may be related to downregulation of renal SGLT2 expression. Studies examining the impact of SGLT2i on markers of kidney disease in patients with other causes of nondiabetic CKD are needed.

Indexed as

AdultAnimalsArteriolesBenzhydryl CompoundsDisease Models, AnimalFemaleGlomerular Filtration RateGlomerulosclerosis, Focal SegmentalGlucosidesHumansKidneyMaleMiddle AgedPilot ProjectsProof of Concept StudyProteinuriaBenzhydryl CompoundsdapagliflozinGlucosidesSLC5A2 protein, humanSlc5a2 protein, ratSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsFSGSnondiabetic CKDSGLT2 inhibition

Identifiers

PMID29141939
PMCPMC5899226
OpenAlexW2769932926

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.